672-47-9

Basic information

• Product Name: 2-(TRIFLUOROMETHYL)PYRIMIDINE-4,6-DIOL
• Synonyms: IFLAB-BB F2124-0816;2-(TRIFLUOROMETHYL)PYRIMIDINE-4,6-DIOL;4-hydroxy-2-(trifluoromethyl)-1H-pyrimidin-6-one;4,6-Dihydroxy-2-trifluoromethylpyrimidine;6-hydroxy-2-(trifluoromethyl)-4(1H)-Pyrimidinone;NSC 52339;2-trifluoromethyl-1H-pyrimidine-4,6-dione;2-(TRIFLUORORIMMETHYL)PYIDINE-4,6-DIOL
• CAS NO: 672-47-9
• Molecular Formula: C₅H₃F₃N₂O₂
• Molecular Weight: 180.08
• Mol File: 672-47-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 254-256℃
• Boiling Point: 228.5 °C at 760 mmHg
• Flash Point: 92 °C
• Appearance: /
• Density: 1.75
• Vapor Pressure: 0.0486mmHg at 25°C
• Refractive Index: 1.516
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.00±0.10(Predicted)
• CAS DataBase Reference: 2-(TRIFLUOROMETHYL)PYRIMIDINE-4,6-DIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(TRIFLUOROMETHYL)PYRIMIDINE-4,6-DIOL(672-47-9)
• EPA Substance Registry System: 2-(TRIFLUOROMETHYL)PYRIMIDINE-4,6-DIOL(672-47-9)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT, AVOID SKIN CONTACT
• Hazardous Substances Data: 672-47-9(Hazardous Substances Data)

Usage

General Description

2-(trifluoromethyl)pyrimidine-4,6-diol is a chemical compound with the molecular formula C5H3F3N2O2. It is a fluorinated pyrimidine derivative that has two hydroxyl groups attached to the 4 and 6 positions of the pyrimidine ring. 2-(TRIFLUOROMETHYL)PYRIMIDINE-4,6-DIOL has potential applications in the pharmaceutical industry, particularly in the development of new drugs. It can also be used as a building block in organic synthesis. Its unique structure and properties make it an interesting target for research and development in various fields, including medicinal chemistry and materials science.

InChI:InChI=1/C5H3F3N2O2/c6-5(7,8)4-9-2(11)1-3(12)10-4/h1H,(H2,9,10,11,12)

Upstream product

• 354-37-0 trifluoroacetamidine 
• 105-53-3 diethyl malonate 
• 108-13-4 malonodiamide 
• 431-47-0 trifluoroacetic acid-methyl ester 
• 354-38-1 2,2,2-trifluoroacetamide 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 715-46-8 4,6-dichloro-5-nitro-2-trifluoro-methyl-pyrimidine 
• 2344-17-4 4,6-dichloro-2-trifluoromethyl-pyrimidin-5-ylamine 
• 1305117-36-5 N₄-{[(2S)-4-Benzylmorpholin-2-yl]methyl}-6-chloro-2-(trifluoromethyl)pyrimidine-4,5-diamine 
• 1305117-37-6 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-7-chloro-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 1305115-74-5 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine 
• 1305115-80-3 PF-04957325 
• 1397685-89-0 C₁₆H₂₁F₃N₆O 
• 1397685-90-3 C₁₈H₁₉F₃N₆O₂ 
• 1397685-95-8 C₁₈H₁₉F₃N₆O 
• 1397685-96-9 C₁₈H₁₈F₄N₆O 
• 1397686-01-9 C₁₈H₁₉F₃N₆O₂ 
• 24903-69-3 4-methoxy-2-trifluoromethylpyrimidine 
• 1514-96-1 4-chloro-2-(trifluoromethyl)pyrimidine 
• 1546-80-1 2-trifluoromethyl-4-hydroxypyrimidine 

Relevant articles and documents

Preparation method of 4-chloro-2-trifluoromethyl pyrimidine

The invention discloses a preparation method of 4-chloro-2-trifluoromethyl pyrimidine (formula I). According to the preparation method, cheap and easily purchased methyl trifluoroacetate and malonamide are taken as the raw materials. The preparation method has the advantages that no pricy material is used, the reaction conditions are mild, the used equipment is simple, the EHS risk is little, the cost is low, and the preparation method is suitable for massive production.

SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS

Compounds of Formula (I): wherein R1 , R2, R3, R4, and R5 are as defined herein, are disclosed.

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I) in free base form or in acid addition salt form, in which R1, R2, R3, R4 and A are as defined in the specification, to their preparation, to their use as medicaments for the treatment of certain nervous system disorders and to medicaments comprising them.